EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

European Medicines Agency re-organisation

Supporting the work of the committees

Presentation to the PCWP/HCPWP joint meeting – 25 September 2013

Presented by Isabelle Moulon
Head of Patients and Healthcare Professionals

New organisation structure to focus on three key elements

- Better support the scientific work of the EMA committees
- Better share the knowledge and information the Agency holds throughout the European Union (EU) medicines regulatory network
- Better meet the needs of our stakeholders and partners.

New organisation structure: reason why

Reshaping a regulatory agency fit for the future

- Economic pressures
- New challenges, e.g. future legislative and policy challenges
- To do more with less: a more effective and efficient use of existing resources

New organisation structure



New organisation structure - main changes

- Creation of four new Divisions dealing with medicines for human use

- New Division for stakeholders and communication to provide improved coordination of the Agency's relations with stakeholders
- No change for the current entities responsible for veterinary medicines, IT and administration
- Advisory functions, which provide advice the Executive Director on operational and scientific issues in their fields of expertise.

The start of a journey

- The Agency will be looking at all operations over the course of next 12-18 months to design processes and refine structure.

The transition to the new structure started on 1 August 2013



The new structure and revised operational processes will be completed in 2014



- Throughout the transition period we will ensure continuity of operations for medicine evaluation and supervision

What it means for now

- The continuity of the EMA’s operations will be ensured at all times during the period of reorganisation.
- All contact points will remain unchanged for the time being.
- Any changes that will be made will be communicated to the EMA’s stakeholders.